Can I Take Rhodiola with Tresiba (Insulin Degludec)?

The Short Answer: Yes, There Is an Interaction Worth Taking Seriously

Rhodiola rosea is not a neutral supplement for women on insulin. Animal and early human data suggest it can lower fasting glucose and improve insulin sensitivity, which sounds appealing but means it adds to the glucose-lowering effect of Tresiba. The result is a higher chance of hypoglycemia, particularly overnight, given that insulin degludec has a flat, ultra-long action profile lasting up to 42 hours.

This interaction is pharmacodynamic. That means the two substances are working through separate biological pathways, but their effects on blood glucose point in the same direction. No timing trick, like taking rhodiola in the morning and Tresiba at night, eliminates the overlap. Their effects are always on board together.

Women carry additional variables that amplify this concern: cycle-related insulin sensitivity shifts, the hormonal disruptions of perimenopause, and the particular metabolic profile of polycystic ovary syndrome (PCOS). Each of those factors changes where your baseline glucose sits before you add two blood-sugar-lowering agents.

How Tresiba Works

Mechanism and Duration

Insulin degludec (Tresiba) is a long-acting basal insulin analogue. After subcutaneous injection, it forms soluble multi-hexamers that create a subcutaneous depot, releasing insulin slowly and steadily into the bloodstream. Its half-life is approximately 25 hours, and steady-state is reached after two to three days of once-daily dosing. Its duration of action extends beyond 42 hours, longer than any other approved basal insulin.

Why This Duration Matters for Supplement Interactions

Because Tresiba is always working at a relatively constant level, there is no "low-insulin window" during your day when adding a glucose-lowering supplement becomes safe. Glargine U-100, for comparison, has a shorter, more variable profile. Tresiba's stability is its clinical strength. It also means that any agent adding to its glucose-lowering effect does so around the clock.

Approved Indications

The FDA approved insulin degludec for adults and children aged one year and older with type 1 diabetes, and for adults with type 2 diabetes. The approved dose range for type 2 diabetes starts at 10 units once daily, titrated to fasting glucose targets.

How Rhodiola Works and Why It Affects Blood Sugar

What Rhodiola Rosea Actually Does

Rhodiola rosea is an adaptogenic herb from Arctic and mountainous regions. Its primary active constituents are rosavins and salidroside. Supplement companies market it for stress resilience, fatigue, mood, and increasingly for "metabolic support" and PCOS. That last claim is where the pharmacodynamic overlap with insulin begins.

Salidroside has been shown in cell and animal studies to activate AMP-activated protein kinase (AMPK), the same energy-sensing enzyme that metformin activates. AMPK activation increases glucose uptake in skeletal muscle and suppresses hepatic glucose production. In a rodent model, salidroside treatment reduced fasting blood glucose and improved glucose tolerance on oral glucose tolerance testing.

MAOI-Like and Serotonergic Properties

Rhodiola also has mild monoamine oxidase inhibitor (MAOI)-like activity. This is relevant beyond the glucose question because MAO inhibitors can independently affect glucose regulation by altering catecholamine metabolism. Epinephrine and norepinephrine are counter-regulatory hormones; anything that shifts their clearance may blunt the normal hormonal response to hypoglycemia, making it harder for your body to recover from a low on its own. A 2009 study in Phytomedicine documented this MAOI activity in standardized rhodiola extract, with the effect attributed primarily to rosavin fractions.

Human Evidence: Limited but Real

Direct human trials of rhodiola on glycemic outcomes are thin. Most data come from animal models or in vitro work. A small randomized trial in Phytotherapy Research (2016) found that rhodiola supplementation reduced stress-related fatigue and modestly improved HbA1c in a non-diabetic cohort with metabolic syndrome, but the study enrolled 80 participants, was not powered for glycemic endpoints, and did not involve people on insulin. Extrapolating from that to a woman on Tresiba requires caution.

The WomanRx Interaction Framework for Adaptogens Plus Basal Insulin: When an adaptogen has AMPK-activating, insulin-sensitizing, or MAOI-like activity, combine it with a long-acting insulin only under direct prescriber supervision with a defined glucose monitoring plan. The absence of a published case report of severe hypoglycemia is not evidence of safety; it reflects the near-total absence of studied populations.

The Pharmacodynamic Interaction in Detail

Two glucose-lowering forces acting simultaneously on the same physiological target is the core problem. Tresiba suppresses hepatic glucose output and drives glucose into muscle and fat. Rhodiola, via AMPK activation and possible insulin-sensitizing effects, pushes the same levers.

Natural Medicines database rates this combination as a moderate interaction, flagging the additive hypoglycemic potential based on salidroside's mechanistic profile. The Mayo Clinic drug-interaction checker similarly lists blood-glucose-lowering herbs as agents requiring caution with insulin products.

There is no pharmacokinetic component here. Rhodiola does not meaningfully affect the enzymes (primarily tissue uptake rather than cytochrome P450) that clear insulin degludec. The two agents do not compete for protein binding or alter each other's absorption. The risk is entirely about what they do to your glucose once they are both on board.

Women-Specific Considerations Across Life Stages

Reproductive Years and the Menstrual Cycle

Insulin sensitivity fluctuates across the menstrual cycle in women with type 1 and type 2 diabetes. During the luteal phase, progesterone rises and insulin sensitivity falls; many women require 10 to 25 percent more insulin in the five to seven days before menstruation. If you add rhodiola's glucose-lowering effect during the follicular phase, when your baseline sensitivity is already higher, the additive hypoglycemia risk is at its peak.

Tracking your cycle alongside your continuous glucose monitor (CGM) or fingerstick log is genuinely useful if you are combining these agents. A pattern of overnight lows in weeks two and three of your cycle, but not weeks three and four, would point toward this interaction as a contributing factor.

PCOS

Women with PCOS are disproportionately likely to search for rhodiola because it is marketed as a natural option for stress, cortisol management, and insulin resistance, three real features of PCOS. Some women with PCOS who are on insulin (either because they have progressed to type 2 diabetes or because they have type 1 diabetes with comorbid PCOS) will encounter this combination directly.

PCOS is associated with insulin resistance in 65 to 80 percent of affected women, which is precisely why rhodiola's AMPK-activating properties sound appealing. The concern is that in a woman already on a titrated insulin dose, adding an additional insulin-sensitizing agent without adjusting the Tresiba dose may push glucose too low. Talk to your endocrinologist or prescribing NP before starting rhodiola if you have PCOS and are on any insulin.

Perimenopause and Menopause

The hormonal shifts of perimenopause introduce significant glycemic variability. Estrogen supports insulin sensitivity; as estrogen levels decline erratically during perimenopause, blood glucose can swing unpredictably even without any medication change. A 2020 analysis in Menopause confirmed that perimenopausal women show measurable worsening of glucose homeostasis compared to premenopausal controls, independent of weight gain.

Rhodiola is also frequently marketed for perimenopausal mood and energy complaints. The supplement has genuine evidence for fatigue and stress, which makes it tempting during a period when many women feel burned out. If you are perimenopausal, on Tresiba, and considering rhodiola for energy or mood, the safer first step is reviewing your Tresiba dose with your provider before adding anything glucose-active.

Trying to Conceive and Pregnancy

Tresiba in pregnancy carries an FDA Pregnancy Category B designation, meaning animal studies showed no fetal harm, but adequate and well-controlled studies in pregnant women are limited. The ACOG Practice Bulletin on pregestational diabetes notes that insulin is the preferred agent for diabetes management in pregnancy, and long-acting analogues including degludec may be used when clinically appropriate, with careful glucose monitoring.

Rhodiola in pregnancy: do not use. There are no human safety data in pregnancy. Animal studies suggest potential uterotonic effects. Given the absence of safety data and the theoretical risk, rhodiola should be stopped before conception attempts and is contraindicated throughout pregnancy.

If you are trying to conceive and currently taking both Tresiba and rhodiola, stop rhodiola first, then work with your endocrinologist to re-titrate your Tresiba dose, because removing the additive insulin-sensitizing effect of rhodiola may require a dose increase.

Lactation and Postpartum

Insulin degludec transfers minimally into breast milk and is considered compatible with breastfeeding. The American Diabetes Association Standards of Care note that insulin does not pose a meaningful risk to nursing infants because it is a protein that is digested rather than absorbed systemically in the infant's gut.

Rhodiola data in lactation are absent. With no human pharmacokinetic data on transfer into breast milk and no infant safety studies, the conservative position is avoidance during breastfeeding. The postpartum period also brings rapid, unpredictable changes in insulin sensitivity as prolactin, estrogen, and progesterone shift. Adding a glucose-active supplement to a basal insulin that was already titrated to a pregnancy or immediate-postpartum requirement creates unnecessary complexity.

What to Do If You Are Already Taking Both

First, do not stop either abruptly without guidance.

Check your glucose log or CGM for patterns: unexplained lows, particularly overnight or in the early morning, suggest the combination is pulling glucose too far down. Look for readings below 70 mg/dL (3.9 mmol/L) that do not coincide with missed meals, unusual exercise, or other identifiable causes.

The American Diabetes Association defines clinically significant hypoglycemia as a glucose <54 mg/dL (3.0 mmol/L), regardless of symptoms. If you are seeing readings at or below that threshold, contact your prescriber the same day.

Bring your rhodiola bottle to your next appointment. Dose, standardization (percent rosavins and salidrosides), and brand quality vary widely, and your provider needs to know exactly what you are taking to make a clinical decision.

Your provider may: lower your Tresiba dose by 10 to 20 percent and recheck fasting glucose at two weeks; ask you to discontinue rhodiola and monitor for glucose rise; or keep both and increase your CGM targets to catch lows earlier.

Monitoring Plan If Your Provider Approves the Combination

Some women have valid reasons to trial rhodiola even on insulin, for example, significant fatigue during chemotherapy for breast cancer with comorbid type 1 diabetes, where the adaptogenic evidence is stronger. In those cases, a structured monitoring plan matters.

The minimum reasonable monitoring protocol includes:

• Baseline period: one to two weeks of fasting and bedtime glucose checks before starting rhodiola, recorded daily.
• Initiation phase: fingerstick or CGM checks before bed and upon waking for the first four weeks after adding rhodiola.
• Hypoglycemia threshold: any fasting glucose below 80 mg/dL (4.4 mmol/L) on two consecutive days prompts a call to your provider.
• HbA1c recheck: at three months, since an unexpectedly lower HbA1c compared to prior trend may indicate consistent additive lowering from rhodiola.
• Symptom log: night sweats, palpitations, and morning headaches in a woman on basal insulin and an adaptogen may represent nocturnal hypoglycemia rather than perimenopausal symptoms.

Who This Combination Is Not Right For

Women who should avoid combining rhodiola with Tresiba without direct specialist oversight include:

• Anyone with a history of severe hypoglycemia or hypoglycemia unawareness.
• Women who are pregnant or breastfeeding (stop rhodiola, full stop).
• Women who are actively trying to conceive.
• Women with type 1 diabetes who have highly variable glucose patterns or who do not use CGM.
• Women on concurrent medications that also lower glucose: SGLT2 inhibitors, GLP-1 receptor agonists, or sulfonylureas.
• Anyone taking other serotonergic medications, given rhodiola's serotonergic and MAOI-like properties, which raise the theoretical risk of serotonin syndrome.

Evidence Gaps: What We Do Not Know

Women have been consistently underrepresented in herbal supplement research. The salidroside studies that form the mechanistic basis for rhodiola's glucose-lowering effect were conducted predominantly in male rodents and male human participants. A 2021 review in Nutrients noted the complete absence of sex-stratified analyses in the rhodiola clinical trial literature.

We do not know:

• Whether the AMPK-activating effect of salidroside differs by menstrual cycle phase.
• Whether estrogen modulates rhodiola's metabolic effects.
• What dose of rhodiola produces clinically meaningful glucose lowering in women on basal insulin.
• Whether the MAOI-like activity blunts counter-regulatory hormone responses in women specifically.

These are not minor gaps. They mean every clinical recommendation about this combination in women is extrapolated from male-dominant or non-diabetic data. This article, and any clinician advising you on this topic, is working with incomplete information. That is not a reason for paralysis, but it is a reason to monitor more carefully rather than less.

The Serotonergic and MAOI Concern: A Separate Safety Signal

Beyond blood glucose, rhodiola's MAOI-like activity creates a second interaction concern for women on any serotonergic medication: antidepressants, certain migraine treatments (triptans), or tramadol. Many women with diabetes also manage depression or migraine, which are more prevalent in women than men.

A 2016 case report in the Journal of Clinical Psychopharmacology described serotonin-related symptoms in a patient taking rhodiola alongside a selective serotonin reuptake inhibitor (SSRI). While Tresiba itself does not interact serotonergically, if you are on Tresiba plus an SSRI or SNRI and considering adding rhodiola, you are layering a third interaction risk on top of the glucose concern. Your pharmacist is the right person to review your full medication and supplement list before you start.

Talking to Your Provider: What to Actually Say

Many women feel dismissed when they bring up supplements. Come prepared with specifics.

Say: "I want to try rhodiola rosea, standardized to three percent rosavins and one percent salidrosides, at 400 mg once daily. I understand there is a pharmacodynamic interaction with my Tresiba because rhodiola activates AMPK and may increase my insulin sensitivity. Can we build a monitoring plan before I start?"

That framing signals that you have done your research, names the mechanism, specifies the dose and standardization you intend to use, and asks for a collaborative plan rather than a simple yes or no. It changes the clinical conversation.